We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Diabetes & Endocrinology

Evaluating Beta Cell Function in Preclinical Type 1 Diabetes Using CGM-Derived Disposition Index

MedXY Editorial Team•Oct 14, 2026•Diabetes & Endocrinology
Beta-cell functioncontinuous glucose monitoringIslet Autoimmunitytype 1 diabetes
Evaluating Beta Cell Function in Preclinical Type 1 Diabetes Using CGM-Derived Disposition Index

Highlight

Study Background

Study Design

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Efficacy and Safety of the twiist Automated Insulin Delivery System in Insulin-Treated Type 2 Diabetes: A Comprehensive Review of the twiist-T2D Pivotal Trial and Related EvidenceThe twiist AID system significantly improves glycemic control and patient satisfaction in insulin-treated type 2 diabetes over 13 weeks, demonstrating safety and effectiveness supported by complementary real-world and RCT data.Oct 16, 2026Optimizing Insulin Therapy with Continuous Glucose Monitoring in Nocturnal Parenteral Nutrition PatientsContinuous glucose monitoring-guided insulin optimization improves glycemic control and nutritional status in insulin-treated adults receiving long-term nocturnal parenteral nutrition, reducing hyperglycemia and associated complications.Oct 15, 2026Impact of School Care Locations on Glycemic Control in Children with Type 1 Diabetes: Insights from a Japanese Multicenter StudyThis study explores how the choice of diabetes self-care location at school affects glycemic control in children with Type 1 diabetes, highlighting restroom use as a risk factor for poorer outcomes and emphasizing the need for supportive scOct 13, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Cardiology
Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
CGM Versus OGTT in Early-Stage Type 1 Diabetes: Comparative Predictive Accuracy and Clinical ImplicationsThis review synthesizes evidence demonstrating that continuous glucose monitoring (CGM) metrics, particularly time above 140 mg/dL, predict progression to stage 3 type 1 diabetes with accuracy comparable to oral glucose tolerance test (OGTTOct 11, 2026
Unraveling Maternal Protection Against Type 1 Diabetes: Genetic Risk and Intrauterine InfluencesThis study reveals that the reduced risk of type 1 diabetes in children born to mothers with the condition is not due to genetic differences but possibly to protective intrauterine exposures during early childhood.Oct 7, 2026
Enhanced Glycaemic Control in Type 2 Diabetes: Digital Therapeutic Glucura Combined with CGM Shows Superior 6-Month OutcomesA randomized trial demonstrates that adding the digital therapeutic glucura to intermittent CGM and standard care significantly improves HbA1c, weight loss, and mental health in non-insulin-treated type 2 diabetes patients over six months.Oct 7, 2026